コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
3 A safe, affordable, and highly immunogenic meningococcal A conjugate vaccine (PsA-TT, MenAfriVac) w
5 cation (Africa and globally), development of meningococcal A disease vaccination campaigns in Africa,
6 In 2010, mass vaccination with a then-new meningococcal A polysaccharide-tetanus toxoid protein co
7 in LMICs, and the roll out of the MenAfriVac meningococcal A vaccine in the African Meningitis Belt r
10 lution of the Neisseria, the epidemiology of meningococcal and gonococcal disease, and mechanisms of
11 nderstanding the variable pathophysiology of meningococcal and gonococcal infections given that after
12 itu hybridization (FISH) probes specific for meningococcal and gonococcal rRNA were used to demonstra
14 ional validation datasets from patients with meningococcal and inflammatory diseases, bacterial infec
15 ren younger than 15 years with H influenzae, meningococcal and pneumococcal meningitis, and septicaem
16 nduces long-term sustained levels of group A meningococcal antibodies for up to 5 years after vaccina
18 factor H-binding proteins representative of meningococcal B epidemiologic diversity; an hSBA titer o
19 cited bactericidal responses against diverse meningococcal B strains after doses 2 and 3 and was asso
21 effectiveness of the outer membrane vesicle meningococcal B vaccine (MeNZB) against gonorrhoea in yo
23 survey, 20%-24% of participants carried any meningococcal bacteria and 4% carried serogroup B by rt-
24 13, CRM-conjugated) at 2-4 months and 1 or 2 meningococcal C vaccine (MCC-CRM- or MCC-TT) doses at 3-
26 MenB-4C do not have a large, rapid impact on meningococcal carriage and are unlikely to provide herd
29 ningococcal conjugate vaccine on serogroup Y meningococcal carriage and to define the dynamics of car
39 suggesting MenB-FHbp does not rapidly reduce meningococcal carriage or prevent serogroup B carriage a
40 in the 3 districts, overall postvaccination meningococcal carriage prevalence was 6.95%, with NmX do
42 rse, MenACWY-CRM and 4CMenB vaccines reduced meningococcal carriage rates during 12 months after vacc
52 xpression states during long-term persistent meningococcal carriage, in part due to continuous exposu
57 nformation on the relation between infecting meningococcal clonal complex (CC), disease course and ou
60 ert consultations recommended that a group A meningococcal conjugate vaccine be developed and introdu
61 of HIV-infected persons with a quadrivalent meningococcal conjugate vaccine in accordance with Advis
62 of this study was to measure the impact of a meningococcal conjugate vaccine on serogroup Y meningoco
63 The regulatory pathway for this new group A meningococcal conjugate vaccine proved to be a useful tr
64 ccessfully scaled up production of a group A meningococcal conjugate vaccine that used SIIL tetanus t
65 participating schools received quadrivalent meningococcal conjugate vaccine that uses diphtheria tox
70 in the African meningitis belt with group A meningococcal conjugate vaccine, MenAfriVac (PsA-TT), di
71 that included the introduction of a group A meningococcal conjugate vaccine, PsA-TT (MenAfriVac), in
72 The recent introduction of a new group A meningococcal conjugate vaccine, PsA-TT (MenAfriVac), in
78 e World Health Organization (WHO) to develop meningococcal conjugate vaccines for sub-Saharan Africa.
80 recent publications on human papillomavirus, meningococcal conjugate, and tetanus and diphtheria toxo
81 following vaccines are reviewed: influenza, meningococcal conjugate, childhood and adolescent/adult
82 ation registry data and serogroup B invasive meningococcal disease (B-IMD) cases notified to public h
88 e information on clinical course of invasive meningococcal disease (IMD) is useful to evaluate cost-e
93 ertaken in separate studies of children with meningococcal disease (n = 24) and inflammatory diseases
98 present a step forward in the battle against meningococcal disease and will help reassure that the va
101 ary 2008 and November 2010, we identified 13 meningococcal disease cases (7 confirmed, 4 probable, an
105 decrease, even as the proportion of invasive meningococcal disease cases caused by serogroup B has in
107 gene family links to host susceptibility to meningococcal disease caused by infection with Neisseria
108 in 33.9% of vaccinees, although no cases of meningococcal disease caused by N. meningitidis B were r
111 England and Wales, the incidence of invasive meningococcal disease has been declining for more than a
114 explanation for the large number of cases of meningococcal disease in immunized patients being treate
115 nation may provide better protection against meningococcal disease in patients treated with an AP-spe
117 a spp. following the eighth case of invasive meningococcal disease in young children (5 to 46 months)
123 nd (PHE) undertakes enhanced surveillance of meningococcal disease through a combination of clinical,
127 additional genes associated with serogroup Y meningococcal disease, and this work would benefit from
128 thogen responsible for outbreaks of invasive meningococcal disease, including among men who have sex
129 l pack of investigations and were tested for meningococcal disease, of whom 148 consented and were en
130 patients are at >1000-fold increased risk of meningococcal disease, vaccination is recommended; wheth
131 ization by commensal Neisseria lactamica and meningococcal disease, we investigated whether controlle
132 a major cause of severe sepsis and invasive meningococcal disease, which is associated with 5-15% mo
133 a multicomponent vaccine against serogroup B meningococcal disease-into the national infant immunisat
144 e very infrequently associated with invasive meningococcal disease; however, those belonging to the '
146 cines have had minimal success in preventing meningococcal epidemics in the meningitis belt of Africa
149 p binds CFH with affinity similar to that of meningococcal fHbp and promotes survival of N. cinerea i
152 ration for the introduction of MenAfriVac, a meningococcal group A conjugate vaccine developed for th
156 d to estimate coverage by 4CMenB of invasive meningococcal group B isolates obtained during 2007-08 i
157 aimed to repeat the MATS survey for invasive meningococcal group B isolates obtained during 2014-15,
158 In 2014-15, 165 of 251 (66%; 95% CI 52-80) meningococcal group B isolates were estimated by MATS to
159 INTERPRETATION: In 2014-15, two-thirds of meningococcal group B isolates were predicted to be cove
160 nce data suggest that outer membrane vesicle meningococcal group B vaccines affect the incidence of g
161 s been declining for more than a decade, but meningococcal group W (MenW) cases have been increasing
164 infection-related adverse events, including meningococcal infections, were observed through the exte
166 pective on regulatory mechanisms involved in meningococcal interaction with epithelial cells, and sug
167 e results suggested that GltT-GltM-dependent meningococcal internalization into HBMEC might be induce
172 tionality between galE1 and galE2 alleles in meningococcal isolates was retained for all serogroups e
174 d from patients and tested with near-patient meningococcal LAMP and the results were compared with th
175 e aimed to assess the diagnostic accuracy of meningococcal LAMP as a near-patient test in the emergen
178 ance induced by the more highly inflammatory meningococcal LOS was correlated with significantly grea
180 ation aged 1-29 years with 1 dose of group A meningococcal (MenA) conjugate vaccine (PsA-TT, MenAfriV
181 elop, test, license, and introduce a group A meningococcal (MenA) conjugate vaccine for sub-Saharan A
184 e vaccines have been used to control group A meningococcal (MenA) epidemics with minimal success.
185 ntry to introduce the multicomponent group B meningococcal (MenB) vaccine (4CMenB, Bexsero) into a pu
186 bp (factor H binding protein), a serogroup B meningococcal (MenB) vaccine, was used to control a coll
187 data exist on the impact of the serogroup B meningococcal (MenB) vaccines MenB-FHbp and MenB-4C on m
188 asured before a booster of a Hib-serogroup C meningococcal (MenC) conjugate vaccine and again 1 week,
190 o- or nasopharynx and the causative agent of meningococcal meningitis and meningococcemia, is capable
193 a pneumococcal seroprevalence study during a meningococcal meningitis epidemic in Western Burkina Fas
196 nsible for epidemics and almost all cases of meningococcal meningitis in the meningitis belt over the
197 eningitis at a time when the epidemiology of meningococcal meningitis on the continent is changing ra
200 a vaccine against the one cause of epidemic meningococcal meningitis that currently cannot be preven
201 nhanced surveillance, no case of serogroup A meningococcal meningitis was reported in the three vacci
207 iagnosed between 20 and 55 years of age with meningococcal (n = 451), pneumococcal (n = 553), or vira
208 among persons who had a history of childhood meningococcal (n=1338), pneumococcal (n=455), and H. inf
210 and wild-type mice immunized with a control meningococcal native outer membrane vesicle vaccine had
213 ed or receiving disability pension in former meningococcal or viral meningitis patients versus member
215 ren presenting at the hospital underwent the meningococcal pack of investigations and were tested for
217 3% (90.6% vs 94.9%; 95% CI, 2.0%-6.6%) fewer meningococcal, pneumococcal, and H. influenzae meningiti
218 of Danish-born children diagnosed as having meningococcal, pneumococcal, or Haemophilus influenzae m
219 accepted technology transfer for the group A meningococcal polysaccharide from SynCo Bio Partners and
220 can be prevented by active immunization with meningococcal polysaccharide or polysaccharide-protein c
223 mophilus influenzae type b (Hib) and group C meningococcal polysaccharides, as well as tetanus toxoid
224 reflect genetic diversity in the underlying meningococcal population rather than novel adaptation to
227 e by whole-genome sequencing and compare the meningococcal population structure of Swedish invasive s
235 the meningitis belt of sub-Saharan Africa, a meningococcal serogroup A conjugate vaccine (MACV) has b
237 blood from 12 healthy adults vaccinated with meningococcal serogroup B and serogroup A, C, W, Y vacci
238 accine approved in the USA for prevention of meningococcal serogroup B disease in 10-25-year-olds.
240 ased vaccines, Bexsero and Trumenba, against meningococcal serogroup B strains have been licensed; bo
241 using human complement (hSBA) by use of four meningococcal serogroup B test strains expressing vaccin
242 e than 50% of participants for three of four meningococcal serogroup B test strains representative of
243 e than 50% of participants for three of four meningococcal serogroup B test strains representative of
245 l countries consider the implementation of a meningococcal serogroup B vaccine for young children and
247 o assess possible herd immunity effects with meningococcal serogroup B vaccines and the need for a bo
249 uring 2001-2005 all provinces introduced the meningococcal serogroup C conjugate vaccine (MCCV) into
250 milarities of meningococcal serogroup W with meningococcal serogroup C emergence, the rapid expansion
251 the PS-specific BMEM induced in humans by a meningococcal serogroup C PS (Men C)-TT conjugate vaccin
252 Hospital admissions decreased after the meningococcal serogroup C vaccine was introduced in 1999
253 tudy, we used national surveillance data for meningococcal serogroup W and serogroup C disease in the
258 TATION: Given the historical similarities of meningococcal serogroup W with meningococcal serogroup C
262 ulted in significantly lower carriage of any meningococcal strain (18.2% [95% CI 3.4-30.8] carriage r
263 evel of lipid A phosphorylation, as LOS from meningococcal strain 89I with the highest degree of phos
264 amount of protein expressed by the different meningococcal strains and this could be predicted from t
266 nfant rats, which could inform the choice of meningococcal strains for use in animal models, and reve
267 ctericidal responses of the 2 groups against meningococcal strains susceptible to antibody to the Nad
271 -related schedules for certain vaccines (eg, meningococcal; tetanus toxoid, reduced diphtheria toxoid
274 ium will allow for a better understanding of meningococcal transcriptome organization and riboregulat
275 y demonstrates how housing density can drive meningococcal transmission and carriage, which likely fa
276 ion documents, all participants had received meningococcal vaccination and the majority of those from
282 During the first introduction of a group A meningococcal vaccine (PsA-TT) in 2010-2011 and its roll
286 cine group than in those in the quadrivalent meningococcal vaccine group (n=60 vs n=37; p=0.02).
287 eported in 60 (3%) women in the quadrivalent meningococcal vaccine group and 61 (3%) women in the tri
288 ere first episodes (n=77 in the quadrivalent meningococcal vaccine group vs n=52 in the trivalent ina
289 93 (88%) of 2041 infants in the quadrivalent meningococcal vaccine group were followed up until age 6
291 was more common in women given quadrivalent meningococcal vaccine than in those given trivalent inac
292 i-TT), Vi-polysaccharide (Vi-PS), or control meningococcal vaccine with a computer-generated randomis
298 f tetanus/diphtheria/acellular pertussis and meningococcal vaccines, respectively, was delayed by 1 w
300 how that capsular polysaccharide, a critical meningococcal virulence factor, inhibits the CP of compl
301 s known or hypothesized to have an impact on meningococcal virulence were shown to be associated with
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。